TABLE 1.

Potential targets for myocardial infarction mRNA therapy.

Reagent	Animal	Dose	Delivery method	Treatment result	Category	Reference
Human recombinant VEGF	Mice	2.4 ng total	PLGA nanoparticle	LVFS: Control: ∼15% Treatment: ∼20%	Angiogenesis	Oduk et al. (2018)
Rat recombinant VEGF	Rat	300 ng total	Alginate microsphere patch	LVFS: Control: ∼20% Treatment: ∼30%		Rodness et al. (2016)
Basic FGF	Mice	14 ng total	Intraperitoneal injection	LVFS: Control: ∼48% Treatment: ∼57%		Rao et al. (2020)
Basic FGF	Rat	5 µg total	Poly(NIPAAm-co-PAA-co-BA) hydorgel	LVFS: Control: ∼25% Treatment: ∼30%		Garbern et al. (2011)
Acidic FGF	Mice	500 ng total	Poly(ethylene argininylaspartate diglyceride)	LVEF: Control: ∼37% Treatment: ∼47%		Wang et al. (2017)
Recombinant human HGF	Mice	160 µg total	Intravenous injection	LVEDP: Control: ∼11 mmHg Treatment: ∼4 mmHg		Nakamura et al. (2000)
CTGF human monoclonal antibody	Mice	10 µg/g, 2 injections	Intraperitoneal injection	LVEF: Control: ∼16.5% Treatment: ∼27.1%	Fibrosis	Vainio et al. (2019)
Pharmaceutical inhibitor for TGF-β receptor (Activin receptor-like kinase 5)	Rat	50 µg/g/day	Gavage	LVEF: Control: ∼43.7% Treatment: ∼51.8		Tan et al. (2010)
Recombinant agrin	Mice	1 µg total	Intramyocardial injection	LVEF: Control: ∼41.9% Treatment: ∼55.0%	Cardiomyocyte proliferation	Bassat et al. (2017)
NOTCH ligand (Jagged-1 mimic)	Rat	N/A	Peptide hydrogel	LVEF: Control: ∼48% Treatment: ∼75%		Boopathy et al. (2015)
Neuregulin-1, EGF-like domain	Mice	2.5 µg total	Intraperitoneal injection	LVEF: Control: ∼22% Treatment: ∼32%		Bersell et al. (2009)

LVFS, left ventricular fractional shortening; LVEF, left ventricular ejection fraction; LVEDP, left ventricular end-diastolic pressure.